2018 AASLD指南：肝细胞癌的治疗

2018-01-06 美国肝病研究学会 Hepatology. 2018 Jan;67(1):358-380.

2018年1月，美国肝病研究学会(AASLD)发布了肝细胞癌的治疗指南。指南更加侧重临床实践，涉及肝硬化患者肝细胞癌的监测，肝细胞癌的诊断及各种治疗方案。

中文标题：

英文标题：

AASLD Guidelines for the Treatment of Hepatocellular Carcinoma

发布机构：

美国肝病研究学会

发布日期：

2018-01-06

简要介绍：

2018年1月，美国肝病研究学会(AASLD)发布了肝细胞癌的治疗指南。指南更加侧重临床实践，涉及肝硬化患者肝细胞癌的监测，肝细胞癌的诊断及各种治疗方案。

拓展指南：与肝细胞癌相关指南：

有关肝细胞癌更多指南

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=535c81c0015a692c, title=2018 AASLD指南：肝细胞癌的治疗, enTitle=AASLD Guidelines for the Treatment of Hepatocellular Carcinoma, guiderFrom=Hepatology. 2018 Jan;67(1):358-380., authorId=null, author=, summary=2018年1月，美国肝病研究学会(AASLD)发布了肝细胞癌的治疗指南。指南更加侧重临床实践，涉及肝硬化患者肝细胞癌的监测，肝细胞癌的诊断及各种治疗方案。 , cover=, journalId=null, articlesId=null, associationId=65, associationName=美国肝病研究学会, associationIntro=美国肝病学会于1950年3月在伊利诺斯州美国肝病学会正式成立。目前已经拥有2,700多名的专家会员和研究员，成为致力于肝病研究和学术交流最为重要的国际性学术组织。该学会除了每年11月左右举行的一年一度的年会外，还联合美国胃肠病协会（AGA， American Gastroenterological Association ）、美国胃肠内镜学会（ASGE ， American Society for Gastrointestinal Endoscopy）和消化外科学会（SSAT， Society for Surgery of the Alimentary Tract）每年举行一次“消化疾病周”学术交流会。该学会拥有HEPATOLOGY和Liver Transplantation两本影响力非常大的专业杂志。, copyright=0, guiderPublishedTime=Sat Jan 06 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=2018年1月，美国肝病研究学会(AASLD)发布了肝细胞癌的治疗指南。指南更加侧重临床实践，涉及肝硬化患者肝细胞癌的监测，肝细胞癌的诊断及各种治疗方案。 拓展指南：与肝细胞癌相关指南： <ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=9e0951c001a86e54" title="亚太肝细胞癌管理临床实践指南推荐意见（2017年更新版）" target=_blank>亚太肝细胞癌管理临床实践指南推荐意见（2017年更新版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c63411c001a859eb" title="《2016年韩国腹部影像学会共识推荐：钆酸增强MRI诊断肝细胞癌》摘译" target=_blank>《2016年韩国腹部影像学会共识推荐：钆酸增强MRI诊断肝细胞癌》摘译</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=df3441c001a568e1" title="2017 APASL亚太临床实践指南：肝细胞癌的管理（更新版）" target=_blank>2017 APASL亚太临床实践指南：肝细胞癌的管理（更新版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=000b51c001a26475" title="2016 KSAR共识建议：应用钆塞酸增强MRI诊断肝细胞癌" target=_blank>2016 KSAR共识建议：应用钆塞酸增强MRI诊断肝细胞癌</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6cf2d1c001a1584c" title="2016 AASLD指南：肝细胞癌的治疗" target=_blank>2016 AASLD指南：肝细胞癌的治疗</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E8%82%9D%E7%BB%86%E8%83%9E%E7%99%8C" target=_blank>有关肝细胞癌更多指南</a></ul>, tagList=[TagDto(tagId=357, tagName=肝细胞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=22, categoryName=肝病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8496, appHits=283, showAppHits=0, pcHits=5636, showPcHits=3636, likes=133, shares=5, comments=3, approvalStatus=1, publishedTime=Wed Jan 24 11:56:29 CST 2018, publishedTimeString=2018-01-06, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Wed Jan 24 11:56:29 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 09:28:14 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 AASLD指南：肝细胞癌的治疗)])

2018 AASLD指南：肝细胞癌的治疗

下载请点击：

评论区 (3)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=282667, encodeId=265a28266e0a, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Sat Jan 27 20:55:28 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281596, encodeId=3157281596d6, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:48:53 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281577, encodeId=15342815e71e, content=了解了解.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:05:33 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
2018-01-27 1e0e5697m83(暂无匿称)

henhao

88 0
[GetPortalCommentsPageByObjectIdResponse(id=282667, encodeId=265a28266e0a, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Sat Jan 27 20:55:28 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281596, encodeId=3157281596d6, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:48:53 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281577, encodeId=15342815e71e, content=了解了解.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:05:33 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
2018-01-24 131****1460

学习了受益匪浅

87 0
[GetPortalCommentsPageByObjectIdResponse(id=282667, encodeId=265a28266e0a, content=henhao, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b10c1938054, createdName=1e0e5697m83(暂无匿称), createdTime=Sat Jan 27 20:55:28 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281596, encodeId=3157281596d6, content=学习了受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed Jan 24 13:48:53 CST 2018, time=2018-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=281577, encodeId=15342815e71e, content=了解了解.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 24 13:05:33 CST 2018, time=2018-01-24, status=1, ipAttribution=)]
2018-01-24 1dd8c52fm63(暂无匿称)

了解了解.谢谢分享

84 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科指南

2018 AASLD指南：肝细胞癌的治疗

相关指南

科室

工具

服务